Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FABOLUS-FASTER: Cangrelor vs Tirofiban vs Prasugrel in STEMI
NCT02978040Phase 4Completed
- Sponsor
- Insel Gruppe
- Start
- Jul 2017
- Primary completion
- Aug 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of cangrelor and tirofiban in ST elevation myocardial infarction (STEMI) (4 arms), sponsored by Insel Gruppe. Primary endpoint: Inhibition of platelet activity with LTA-ADP 20 µmol/l at 30 minutes. Started Jul 2017; status: completed.
02
Drugs
cangrelortirofiban
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT02978040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978040.